Abstract
Cutaneous T-cell lymphoma (CTCL) is typically a skin-infiltrating malignancy of clonally derived CD4+ T lymphocytes. Because the host antitumor response appears to play an important role in disease control, systemic therapeutic agents are used in such a manner as to preserve the integrity of the host antitumor response while selectively targeting the malignant cells. The new biologic response-modifying treatment options currently used to treat CTCL are reviewed.
Cite
CITATION STYLE
Vittorio, C. C., Junkins-Hopkins, J. M., McGinnis, K. S., Shapiro, M., Wysocka, M., Zaki, M. H., … Rook, A. H. (2002). New biologic agents for the treatment of cutaneous T-cell lymphoma. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer. https://doi.org/10.1007/978-3-642-59410-6_37
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
